Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Questions Remain On Gilead’s Remdesivir

Executive Summary

Remdesivir shows ability to yield clinical improvement in moderately ill COVID-19 patients, but data are called ‘modest’ and shorter therapy duration showed better results than longer.

You may also be interested in...



Gilead’s Veklury Approval Shows US FDA’s Existing Regulatory Tools Are Up To The COVID-19 Challenge

The FDA emphasized the rigor of its review of the first COVID-19 therapy, which used few expedited pathways on its way to approval after a two-and-a-half-month review. Post-marketing studies will address remaining concerns about dosing and special populations.

Gilead’s Comparative Analysis To Bolster Remdesivir Draws Criticism

Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.

Gilead Ramps Up Remdesivir Manufacturing, Advances Inhaled Formulation

Gilead will study inhalable remdesivir in volunteers, then hopefully in August as an earlier COVID-19 treatment. Analyst says production of 2m-plus I.V. doses by year-end could mean blockbuster revenues.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142325

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel